Trials / Completed
CompletedNCT00454532
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 For Metastatic Breast Cancer.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Bionovo · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
BZL 101 is an aqueous extract from herba Scutellaria Barbata D. Don of the Lamiaceae family. Preclinical studies suggest that this herb has antitumor activity for breast cancer and preliminary clinical data suggest that it is tolerable in patients with metastatic breast cancer. The overall goals of this Phase I/II trial are to assess the toxicity, maximum tolerated dose, safety and preliminary efficacy of BZL101 for the treatment of advanced metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BZL101 | Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion. |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2009-12-01
- First posted
- 2007-03-30
- Last updated
- 2012-03-16
- Results posted
- 2012-03-16
Source: ClinicalTrials.gov record NCT00454532. Inclusion in this directory is not an endorsement.